▎药明康德内容团队编辑

参考资料：

[1] CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma. Retrieved May 26, 2022, from https://www.businesswire.com/news/home/20220525005944/en

[2] European Commission Grants Conditional Approval of CARVYKTI® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma. Retrieved May 26, 2022, from https://www.janssen.com/european-commission-grants-conditional-approval-carvykti-ciltacabtagene-autoleucel-janssens-first

版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。